2,6-Dimethyl-pyrimidin-carbonsaeure-(4)-amid | 74502-96-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,6-Dimethyl-pyrimidin-carbonsaeure-(4)-amid
• 英文别名: 2,6-dimethyl-pyrimidine-4-carboxylic acid amide；2,6-Dimethyl-pyrimidin-4-carbonsaeure-amid；2,6-dimethyl-4-pyrimidinecarboxamide；2,6-Dimethylpyrimidine-4-carboxamide
• CAS: 74502-96-8
• 化学式: C₇H₉N₃O
• 分子量: 151.168
• InChiKey: GIDQOWFSUAZVNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  68.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2,6-Dimethyl-pyrimidin-carbonsaeure-(4)-amid 在 一水合肼 作用下， 反应 2.0h， 生成 2,6-dimethyl-pyrimidine-4-carboxylic acid benzylidenehydrazide
  参考文献：
  名称：

  Yamanaka, Chemical and pharmaceutical bulletin, 1958, vol. 6, p. 633,634

  摘要：

  DOI：
• 作为产物：
  描述：

  2,6-二甲基嘧啶-4-甲腈 在 双氧水 、 碳酸氢钠 、 丙酮 作用下， 生成 2,6-Dimethyl-pyrimidin-carbonsaeure-(4)-amid
  参考文献：
  名称：

  Yamanaka, Chemical and pharmaceutical bulletin, 1958, vol. 6, p. 633,634

  摘要：

  DOI：

文献信息

• Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
  申请人：——

  公开号：US20030069245A1

  公开（公告）日：2003-04-10

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with indoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  这项发明提供了具有药物和生物影响性质的化合物，它们的药物组合物和使用方法。具体而言，该发明涉及吲哚酮乙酰哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂结合使用。更具体地，本发明涉及HIV和艾滋病的治疗。
• 11B-HSD1 inhibitors for the treatment of diabetes
  申请人：Amrien Kurt

  公开号：US20050288308A1

  公开（公告）日：2005-12-29

  Compounds of the formula (I): as well as pharmaceutically acceptable salts and esters thereof, wherein R 1 to R 5 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.

  化合物的公式（I）： 以及其药学上可接受的盐和酯，其中R1至R5具有权利要求1中给定的含义，可以用于制成药物组合物。
• Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
  申请人：Zhang Zaihui

  公开号：US20060247210A1

  公开（公告）日：2006-11-02

  Pharmaceutical pyrazolybenzothiazole compositions of formula (1) are provided. The compositions may be pharmaceutically acceptable salts. R 1 , R 2 and R 3 at each occurrence are independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido, and R 4 is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl.

  提供了公式（1）的药用吡唑基苯并噻唑类化合物。这些化合物可以是药用可接受的盐。每次出现的R1，R2和R3均独立地从氨基，氨基亚磺酰基，氨基磺酰基，芳基，偶氮基，卤素，杂基烷基，杂环基，肼基，烃基，氢，羟基，硝基，亚硝基，磷酸盐，磷酸酯，膦酸盐，膦酸铵，磷代硫酸盐，磷酰基，磺酰胺基，硫酸盐，亚磺酸，磺酸，磺酰基，亚磺酰基，硫醇基，硫脲基和脲基中独立选择，而R4从氢，杂基烷基，杂环基和烃基中选择。
• CANNABINOID RECEPTOR MODULATORS
  申请人：Jones Robert M.

  公开号：US20120214766A1

  公开（公告）日：2012-08-23

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及公式Ia的某些化合物及其制药组合物，其调节大麻素CB2受体的活性。本发明还涉及公式Ia的某些化合物及其制药组合物，其调节CB1受体和CB2受体的活性。本发明的化合物和制药组合物适用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎性疼痛，神经痛，由治疗副作用引起的疼痛和与骨关节炎相关的疼痛；过敏症；炎性过敏症；神经病性过敏症；急性疼痛感受；骨质疏松症；多发性硬化症相关痉挛；自身免疫疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活动和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩性侧索硬化症和帕金森病。
• PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：DERMIRA (CANADA), INC.

  公开号：US20130237572A1

  公开（公告）日：2013-09-12

  Topical formulations and method of using the same are provided. The topical formulation comprises a pyrazolylbenzothiazole derivative of the following formula (1) wherein X, R 1 , R 2 , R 3 and R 4 are described herein.

  提供了一种局部制剂及其使用方法。该局部制剂包括以下式子（1）中的吡唑基苯并噻唑衍生物，其中X，R1，R2，R3和R4的描述如下。